Bioequivalence and Bioavailability Forum

Main page Policy Latest Posts Abbreviations

Proc Mixed for a non-replicate design [Software]

posted by kev – 2010-03-26 11:42 (5507 d 11:40 ago) – Posting: # 4976
Views: 3,629

Many thanks Gents. Both of you're replies seem to support my basic suspicion with the design theory here, that switching from a replicate design to a 4-way-crosssover to confirm treatment effects is a no-go.

Complete thread:

Proc Mixed for a replicate design kev 2010-03-25 16:35
- Posthoc comparisons Helmut 2010-03-25 18:34
- Proc Mixed for a non-replicate design d_labes 2010-03-26 08:48
  - Proc Mixed for a non-replicate designkev 2010-03-26 10:42

Admin contact
23,424 posts in 4,927 threads, 1,668 registered users;
24 visitors (0 registered, 24 guests [including 2 identified bots]).
Forum time: 00:23 CEST (Europe/Vienna)

The difference between a surrogate and a true endpoint
is like the difference between a cheque and cash.
You can get the cheque earlier but then,
of course, it might bounce. Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC

Ing. Helmut Schütz